A2A

A2A Pharmaceuticals has designed new drug candidates for Leukemia and other cancers. A2A has also developed new antibiotics for gram negative bacteria infections.

A2As technology platform allows for optimization of efficacy with minimization of toxicity much faster and more precisely than competitors.

The track record for development of new drug candidates has been proven with work done for other pharmaceutical companies. Details are available on request.

COMPANY PEOPLE

Sridhar Vempati

Sridhar Vempati
Board Member & Co-Founder

Edward Painter

Edward Painter
CEO & Co-Founder

Matthew Welsch

Matthew Welsch
Consultant & Co-Founder

YOU MIGHT ALSO BE INTERESTED IN